Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia

Documenti analoghi

• Diagnostic pitfalls in assessment of ferritin following CAR‐T‐cell therapy: Understanding the hook effect
  di: Roa Harb, et al.
  Pubblicazione: (2024)
• A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
  di: Xing‐yu Cao, et al.
  Pubblicazione: (2024)
• Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia
  di: Tamer Othman, et al.
  Pubblicazione: (2024)
• CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia
  di: Fengjiao Han, et al.
  Pubblicazione: (2025)
• Toxicities and outcome after CD19‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis
  di: Leon D. Kaulen, et al.
  Pubblicazione: (2024)